Compare stocks

Dermapharm Holding SE is a pharmaceutical company based in Germany, specializing in the development, production, and commercialization of off-patent branded pharmaceuticals. The company focuses on several key product segments, including dermatological and allergy products, vitamins, and food supplements. Established in 1991, Dermapharm has developed a diversified product portfolio with over 900 marketing authorizations. It operates production facilities in Europe and maintains a strong sales presence in Germany and other European countries. The company's strategic positioning is bolstered by its vertically integrated business model, which enables efficient product development and manufacturing processes.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.